Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 14

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 1
Chunk 14
---
 split of its then outstanding shares of common stock, with trading of the post-split
shares beginning October 20, 2025 Accordingly, each 10 shares of outstanding common stock then held
by our stockholders were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded
up to the next whole share. Authorized common stock was adjusted accordingly to 6,000,000 shares following the stock split. The reverse
stock split was effected in anticipation of, and to address, a Nasdaq notification regarding noncompliance with the minimum bid price
requirement for continued listing. The accompanying unaudited condensed consolidated financial statements and accompanying notes have
been retroactively revised to reflect such reverse stock split as if it had occurred on April 1, 2024. All shares and per share amounts
have been revised accordingly.

June
2025 Reverse Stock Split

Effective as of the close
of business on June 6, 2025 with an effective trading date of June 9, 2025, we effected a 1-for-8 reverse
stock split of our then outstanding shares of common stock. Accordingly, each 8 shares of outstanding common stock then held by our stockholders
were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole
share. Authorized common stock remained at 60,000,000 shares following the stock split. The accompanying consolidated financial
statements and accompanying notes have been retroactively revised to reflect such reverse stock split as if it had occurred on April 1,
2024. All shares and per share amounts have been revised accordingly.

     11 

September
2025 Registered Direct Offering

On
September 4, 2025, we entered into a Securities Purchase Agreement with certain investors pursuant to which it agreed to sell (i) 4,047,780
shares of common stock, (ii) 952,220 pre-funded warrants, and (iii) 5,000,000 common warrants to purchase up to 5,000,000 shares of common
stock at an exercise price of $0.90 per share. The securities were offered as part of a registered public offering on Form S-1 (File No.
333-289745), which was declared effective by the SEC on September 4, 2025. The combined public offering price for each share (or pre-funded
warrant in lieu thereof) and accompanying common warrant was $